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1. Introduction
HIV is known to be associated with a wide range of immunological and haematological
changes.The immunological changes include depletion in CD4+ T cell, cytokine dysregulation
and immune dysfunction. The dominant immunologic feature of HIV infection is progressive
depletion of the helper T cell (CD4+ T cell), which reverses the normal CD4:CD8 ratio and
subsequently lead to immunodeficiency. CD4+ T cells interact with antigen presenting cells
(APCs), B cells, cytotoxic T cells (CD8+ T cells) as well as natural killer cells. Thus, infection
and depletion of CD4+ T cell population could induce profound immunodeficiency in such
patients.
The haematological changes occur mainly due to several factors such as marrow defects and
immune cytopenias. It is caused by HIV infection, either directly to the bone marrow, oppor‐
tunistic infections, development of lymphoma as a secondary neoplasm and side effects of the
drugs used for the treatment or drugs used for the complicating infection or lymphoma. In
order to further understand the immunological and haematological changes that occur in HIV
infection, the chapter begins with the review of immune system as well as normal haemato‐
poiesis. It further highlights the importance of changes associated with clinical symptoms in
patients with HIV.
2. The human immune system
The immune system plays an important role to protect the host from infectious agents such as
bacteria, viruses, fungi and parasites. In addition, it is also important in the identification and
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elimination of tumor cells as well as in response to injury and trauma. Thus, an effective and
efficient immune system is essential as a host defense mechanism against infectious diseases
and cancer. The immune system can be further subdivided into innate and acquired or
adaptive immunity (Table 1).
Innate immunity Acquired immunity
Physico-chemical barriers Skin Cutaneous and mucosal immune systems
Mucosal membranes Antibodies in mucosal secretions
Lysozyme
Stomach acid
Commensal bacteria in gut
Circulating molecules Complement Antibodies
Immune Cells Granulocytes B lymphocytes
Monocytes/macrophages T lymphocytes
Natural killer cells
Soluble mediators Macrophage-derived cytokines Lymphocyte-derived cytokines
Table 1. Components of the innate and acquired immune systems [1].
2.1. Innate immunity
Innate immunity is the first line of defense mechanism against the invading agents present at
birth. The innate immune system includes physico-chemical barriers, circulating molecules,
immune cells as well as soluble mediators [1, 2]. As compared to acquired immunity, innate
immunity has no memory, poor specificity and has immediate response with lower potency.
2.2. Acquired immunity
The acquired or adaptive immune response is the second line of defense mechanism which
offer better protection against re-exposure to the same pathogen [2]. The acquired immune
system is further subclassified into humoral mediated immunity which involves antibody
production by B lymphocytes and cell mediated immunity comprising CD4+ and CD8+T
lymphocytes. Acquired immunity has immunological memory and it is highly specific. The
specificity occurs because each lymphocyte carries surface receptors for a single antigen [1].
When compared to innate immunity, it has slower response, however it is much more potent
and robust and the response varies among individuals.
Innate and adaptive immune systems as well as complement counteract each other to produce
an effective function and mechanism of eliminating the invading agents.
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2.2.1. B lymphocytes
B lymphocytes are known by their ability to produce antibodies (immunoglobulins), which
are specific for particular antigen [1]. Antibodies work in several ways to combat invading
pathogens. Some pathogens, particularly viruses and some bacteria as well, infect individuals
by entering cells. Some of these pathogens escape humoral immunity and later on will be
encountered by cell-mediated immunity, which is conferred by T lymphocytes.
2.2.2. T lymphocytes
Mature T lymphocytes express T-cell receptors on their surface. They are able to recognize
only those antigens which are associated with the protein termed major histocompatibility
complex (MHC): in humans the MHC is known as human leukocyte antigen (HLA) [2] that
are presented to them on a cell surface by antigen presenting cells (APCs) [2]. When an APC
(e.g. macrophage) encounter an antigen or pathogen, it will engulf, process and present the
pathogen to the T cell [2].
T lymphocytes can be further subdivided into CD4+ T cells (Helper T cells) and CD8+ T cells
(Cytotoxic T cells). CD4+ T cells are further subclassified into Th1 (T helper 1) and Th2 (T helper
2). Th1 is important for eliminating intracellular pathogen whereas Th2 is important for
immunity against extracellular pathogen [2].
The regulation of the immune response is shown in Figure 1. The Th1 cells are involved in cell-
mediated immunity against intracellular pathogens. They produce cytokines such as inter‐
leukin-2 (IL-2), interferon-gamma (IFN-gamma) and interleukin-10 (IL-10) [2]. IL-2 promotes
proliferation of T lymphocytes [2] while IFN-gamma activates the cells involved in the
elimination of pathogens and cells with tumour properties (e.g. monocytes, macrophages,
cytotoxic T lymphocytes, natural killer cells) [1]. By contrast, the Th2 cells are mainly involved
in humoral immunity and immunity against helminthic infection [2]. They produce cytokines
such as IL-4, IL-5, IL-10 and IL-13. It is known that IL-4 stimulates proliferation of B lympho‐
cytes while IL-5 promotes activation of eosinophils [2]. IL-10 has inhibitory effect while IL-13
involves in allergic reaction and helminthic infection [2]. Thus, both Th1 and Th2 cells and
their cytokines counteract with each other to regulate the immune response [1].
The communication within the acquired immune system and between innate and acquired
immunity involves cell surface proteins (e.g. adhesion molecules) and the soluble molecules
which can produce signals from one cell to another, that is called cytokines [1].
2.3. Cytokines
Cytokines are a diverse group of intercellular signaling peptides and glycoproteins with
molecular weight between 6000 and 60,000. They are produced by a variety of tissues and
cells  in response to stimuli  [2].  Cytokines have diverse and pleiotropic  effects  [4].  Their
binding to specific receptors on the cell surface leads to changes in growth, development
or activity of the target cells. They do not only regulate immune and inflammatory responses
but also involve in wound healing, haematopoiesis, angiogenesis as well as other biologic
processes [2, 4].
Immunological and Haematological Changes in HIV Infection
http://dx.doi.org/10.5772/61259
107
3. Immunological aspects of HIV infection
3.1. Clinical features of HIV infection
In primary infection of HIV-1, patients may be asymptomatic though sometimes the disease
is self-limiting. Within the incubation period of about 6 weeks, patients can present with a
mononucleosis-like syndrome, which is characterized by fever, cough, painful swallowing,
myalgias, arthralgias, diarrhea as well as maculopapular rash and lymphadenopathy [5]. In
most circumstances, the symptoms are usually mild as contrasted to severe cases, where
pneumonitis, oropharyngeal and esophageal ulcers may occur. Encephalitis, meningitis,
neuropathy, radiculopathy and myelopathy are not common sickneses in HIV infection.
Although the true incidence of this syndrome is not precisely known, it may also depend on
the degree of exposure to the virus, it may be as high as over 50% in persons who acquire HIV-1
infection [5].
World Health Organization [6] categorized an adult or adolescent (aged > 12 years) as having
AIDS in presence of at least two of the major signs in combination with one of the minor signs
(Table 2).
The diagram shows the mechanism of regulation of immune response. Th1 is mainly involved in cell-mediated im‐
munity and offers protection against intracellular pathogens while Th2 is important in humoral immunity, protection
against helminthic infection as well as allergic or atopic diseases such as allergic rhinitis, asthma etc.
Figure 1. The regulation of immune response [3]
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Major signs Minor signs
⋅ Weight loss of more than 10% bodyweight
⋅ Chronic diarrhea for more than 1 month
⋅ Prolonged fever for more than 1 month (intermittent or
constant)
⋅ Persistent cough for more than 1 month*
⋅ Generalised pruritic dermatitis
⋅ History of herpers zoster
⋅ Oropharyngeal candidiasis
⋅ Chronic progressive or disseminated herpes ⋅ simplex
infection
⋅ Generalised lymphadenopathy
* Persistent cough for more than 1 month should be considered as a minor sign in patients with tuberculosis
Table 2. Major and minor signs of HIV infection [6].
3.2. The classification of HIV disease
The staging and classification of HIV disease are standard tools for monitoring HIV epidemic
and also serve as a guide for clinicians in managing HIV patients. It provides important
information for patients and clinicians regarding the staging of HIV disease and clinical
management. Currently, two major classification are used: World Health Organization (WHO)
Clinical Staging and Disease Classification System and the United State Centers for Disease
Control and Prevention (CDC) Classification System.
The WHO Clinical Staging and Disease Classification System (revised in 2007) is usually used
in resource-constrained settings without access to CD4 cell count measurements or other
diagnostic and laboratory methods [7] The system classifies the HIV disease based on the
clinical manifestations of patients. By contrast, the CDC classification system assesses the HIV
disease severity by CD4 cell count as well as by the presence of specific HIV-related conditions
[7]. This classification system is usually beneficial in the clinical as well as epidemiologic
research.
3.2.1. WHO clinical staging of HIV/AIDS and case definition
The clinical staging and case definition of HIV was developed by WHO in 1990 and revised
in 2007. It is based on the clinical findings rather than CD4 cell count. This staging system has
been used by some countries for managing HIV patients where the CD4 cell count testing is
not available [7]. The staging was categorized as 1 to 4 based on clinical severity and progres‐
sion from primary infection to advanced stage. The adult and adolescents were defined as
individuals aged ≥ 15 years. WHO, 2007 [8] classifies the clinical staging of HIV/AIDS based
on the clinical conditions or symptoms (Table 3).
Clinical Stages Clinical Conditions or Symptoms
Primary HIV Infection ⋅ Asymptomatic
⋅ Acute retroviral syndrome
Clinical Stage 1 ⋅ Asymptomatic
⋅ Persistent generalized lymphadenopathy
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Clinical Stage 2 ⋅ Moderate unexplained weight loss (<10% of presumed or measured body weight)
⋅ Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis)
⋅ Herpes zoster
⋅ Angular cheilitis
⋅ Recurrent oral ulceration
⋅ Papular pruritic eruptions
⋅ Seborrheic dermatitis
⋅ Fungal nail infections
Clinical Stage 3 ⋅ Unexplained severe weight loss ("/>10% of presumed or measured body weight)
⋅ Unexplained chronic diarrhea for "/> 1 month
⋅ Unexplained persistent fever for "/> 1 month ("/>37.6ºC, intermittent or constant)
⋅ Persistent oral candidiasis
⋅ Oral hairy leukoplakia
⋅ Pulmonary tuberculosis
⋅ Severe presumed bacterial infection (e.g., pneumonia, empyema, pyomyositis, bone or joint
infection, meningitis, bacteremia)
⋅ Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
⋅ Unexplained anaemia (haemoglobin<8 g/dl)
⋅ Neutropenia (neutrophils <500 cells/µL)
⋅ Chronic thrombocytopenia (platelets < 50, 000 cells/ µL)
Clinical Stage 4 ⋅ HIV wasting syndrome, as defined by the CDC (see Table 1, above)
⋅ Pneumocystis pneumonia
⋅ Recurrent severe bacterial pneumonia
⋅ Chronic herpes simplex infection (orolabial, genital, or anorectal site for "/>1 month or
visceral herpes at any site)
⋅ Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs)
⋅ Extrapulmonary tuberculosis
⋅ Kaposi sarcoma
⋅ Cytomegalovirus infection (retinitis or infection of other organs)
⋅ Central nervous system toxoplasmosis
⋅ HIV encephalopathy
⋅ Cryptococcosis, extrapulmonary (including meningitis)
⋅ Disseminated nontuberculosis mycobacteria infection
⋅ Progressive multifocal leukoencephalopathy
⋅ Candida of the trachea, bronchi, or lungs
⋅ Chronic cryptosporidiosis (with diarrhea)
⋅ Chronic isosporiasis
⋅ Disseminated mycosis (e.g., histoplasmosis, coccidioidomycosis, penicilliosis)
⋅ Recurrent nontyphoidal Salmonella bacteremia
⋅ Lymphoma (cerebral or B-cell non-Hodgkin)
⋅ Invasive cervical carcinoma
⋅ Atypical disseminated leishmaniasis
⋅ Symptomatic HIV-associated nephropathy
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⋅ Symptomatic HIV-associated cardiomyopathy
⋅ Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis)
Table 3. WHO Clinical Staging of HIV/AIDS for Adult and Adolescents [8].
3.2.2. CDC classification system for HIV infection
The CDC classification of HIV/AIDS is based on the level of CD4 cell count and on previously
diagnosed HIV-related conditions (Table 4) [7]. For example, if a patient had met the criteria
for category B but currently is asymptomatic, the patient would remain in category B. The
categorization is shown in Table 5. Patients in categories A3, B3 and C1-C3 are considered to
have AIDS.
CD4 Cell Count Categories
CLINICAL CATEGORIES
A: Asymptomatic, Acute
HIV or PGL
*B: Symptomatic
Conditions, not A or C
**C: AIDS-Indicator
Conditions
1. ≥ 500 cells/µL A1 B1 C1
2. 200-499 cells/µL A2 B2 C2
3. < 200 cells/µL A3 B3 C3
PGL: persistent generalized lymphadenopathy for *B and **C Clinical Categories refer to Table 5
Table 4. CDC Classification System for HIV-Infected Adults and Adolescents [7].
*Category B:
Symptomatic Conditions
Definition: Symptomatic conditions occurring in an HIV-infected
adolescent or adult that meet at least one of the following criteria:
1. They are attributed to HIV infection or indicate a defect in cell-mediated
immunity
2. They are considered to have a clinical course or management which is
complicated by HIV infection
3. Include the following:
⋅ Bacillary angiomatosis
⋅ Oropharyngeal candidiasis (thrush)
⋅ Vulvovaginal candidiasis, persistent or resistant
⋅ Pelvic inflammatory disease (PID)
⋅ Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
⋅ Hairy leukoplakia, oral
⋅ Herpes zoster (shingles), involving two or more episodes or at least one
dermatome
⋅ Idiopathic thrombocytopenic purpura
⋅ Constitutional symptoms, such as fever ("/>38.5°C) or diarrhea lasting "/>1
month
⋅ Peripheral neuropathy
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**Category C:
AIDS-Indicator Conditions
⋅ Bacterial pneumonia, recurrent (two or more episodes in 12 months)
⋅ Candidiasis of the bronchi, trachea, or lungs
⋅ Candidiasis, esophageal
⋅ Cervical carcinoma, invasive, confirmed by biopsy
⋅ Coccidioidomycosis, disseminated or extrapulmonary
⋅ Cryptococcosis, extrapulmonary
⋅ Cryptosporidiosis, chronic intestinal ("/>1 month in duration)
⋅ Cytomegalovirus disease (other than liver, spleen, or nodes)
⋅ Encephalopathy, HIV-related
⋅ Herpes simplex: chronic ulcers ("/>1 month in duration), or bronchitis,
pneumonitis, or esophagitis
⋅ Histoplasmosis, disseminated or extrapulmonary
⋅ Isosporiasis, chronic intestinal ("/>1-month in duration)
⋅ Kaposi sarcoma
⋅ Lymphoma, Burkitt, immunoblastic, or primary central nervous system
⋅ Mycobacterium avium complex (MAC) or Mycobacterium kansasii,
disseminated or extrapulmonary
⋅ Mycobacterium tuberculosis, pulmonary or extrapulmonary
⋅ Mycobacterium, other species or unidentified species, disseminated or
extrapulmonary
⋅ Pneumocystis jiroveci (formerly carinii) pneumonia (PCP)
⋅ Progressive multifocal leukoencephalopathy (PML)
⋅ Salmonella septicemia, recurrent (nontyphoid)
⋅ Toxoplasmosis of brain
⋅ Wasting syndrome caused by HIV (involuntary weight loss "/>10% of
baseline body weight) associated with either chronic diarrhea (two or more
loose stools per day for ≥1 month) or chronic weakness and documented
fever for ≥1 month
Table 5. B and **C Clinical Categories of HIV infection [7].
3.3. Immunologic changes in HIV infection
3.3.1. Depletion of CD4+T cells causes immunodeficiency
Untreated HIV-1 infection is associated with a gradual loss of peripheral CD4+ T cells. Loss of
CD4+ T cells and systemic immune activation are the major hallmarks of HIV infection [9].
There are two major phases of HIV disease, acute and chronic infection. Acute infection is
associated with gradual loss of CD4+ T cells in the mucosal tissue [10] while chronic infection
is characterized by immune activation which is associated with massive production of
proinflammatory cytokines [11]. This subsequently leads to decrease in peripheral CD4+ T cells
and profound immunodeficiency.
The major mechanism of CD4+ T cell depletion in HIV patients is due to apoptosis, in which
the number of apoptotic cells exceed the number of HIV-infected cells [12]. Other causes
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of CD4+ T cell depletion include impairment of de novo production of T lymphocytes by the
thymus  [9],  induction  of  syncytium  formation,  alteration  of  membrane  permeability,
mitochondrial dysfunction as well as killing by HIV-specific CD8+ T cells due to immune
activation [9].
3.3.2. Loss of function of CD4+ T cells
Functional defects in the immune system of HIV-infected individuals exacerbate the immune
deficiency caused by depletion of CD4+ T cells. These functional defects include a decrease in
T cell responses to antigens as well as weak humoral immune responses even though total
serum Ig levels may be elevated [13]. The defects might be due to the direct effects of HIV on
CD4+ T cells through:
1. Binding of gp120 (viral encoded membrane glycoprotein) to newly synthesized intracel‐
lular CD4+ T cells that result in the interference of normal protein processing in the
endoplasmic reticulum as well as block the surface expression of CD4+ T cells.This makes
the cell incapable of responding to antigenic stimulation and,
2. CD4+ T cells which bound to gp120 may not be available to interact with class II major
histocompatibilty complex (Class II MHC) molecules on antigen presenting cells (APCs),
thus T cell responses to antigens would be inhibited. Alternatively, gp120 binding to
CD4+ may deliver signals that downregulate helper T cell function.
In addition, HIV-infected T cells are unable to form tight synapses with APCs, therefore
interferes with T cell activation [13]. Failure of the activation process will lead to incapability
of the T cells particularly CD4+ T cells to interact with other immune cells and subsequently
lead to failure of elimination of the virus [13].
3.3.3. Cytokine dysregulation and coagulopathy in HIV infection
Cytokines play an important role in controlling the homeostasis of the immune system.
Cytokine dysregulation is a major immunopathogenic factor in HIV infection [14]. The rise in
serum levels of pro-inflammatory and inflammatory cytokines contribute to viral replication
and many manifestations of immunodeficiency [15]. Cytokine production can increase viral
replication due to its activation role in HIV infected cells [16]. Such cytokines include IL-2, IL-4
and interferon type II (IFN-γ) which primarily are required for expansion aid of antiviral T
cells and antibody responses [16].
3.3.3.1. Cytokine dysregulation
Infection with HIV results in dysregulation of the cytokine profile in vivo and in vitro. During
the course of HIV-1 infection secretion of T-helper 1 (Th1) cytokines, such as interleukin (IL)-2
and antiviral interferon (IFN)-gamma important for intracellular infection is generally
decreased, whereas production of T-helper 2 (Th2) cytokines required for extracellular
infection such as IL-4, IL-10, proinflammatory cytokines (IL-1, IL-6, IL-8) and tumour necrosis
factor (TNF)-alpha, is increased [13, 14, 17]. This altered balance of Th1 and Th2 responses may
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partially explain the susceptibility of HIV-infected individuals to infection by intracellular
microbes. In addition, Th2 cytokines also may inhibit macrophage-mediated killing of
microbes [13] and consequently lead to failure of macrophage activation in the killing process
of the virus.
Tumour necrosis factor-alfa (TNF)-α, IL-1 and IL-6 which are produced by monocytes and
macrophages, play an important role in activation of neutrophils, monocytes and macrophages
to initiate bacterial and tumor cell killing, increase adhesion molecule expression on the surface
of neutrophils and endothelial cells, stimulate T and B lymphocytes proliferation as well as
initiate the production of other proinflammatory cytokines [1, 2]. In addition, these cytokines
can cause systemic symptoms such as fever and weight loss as well as influence the production
of acute phase protein in the liver [1]. Inflammation is one of the components of innate immune
response. Thus, production of appropriate amounts of TNF, IL-1 and IL-6 is important in
response to infection [1]. Increased production of these cytokines, particularly TNF-α has been
found in acute and inflammatory conditions (e.g., trauma, sepsis, infection, rheumatoid
arthritis) [18]. The observed increase in proinflammatory and inflammatory cytokines
following cell injury or infection subsequently leads to immune dysfunction.
3.3.3.2. Coagulopathy in HIV patients
Normal levels of protein S, protein C and antithrombin activities are necessary for coagulation
process. In HIV patients, protein S, protein C and antithrombin activities decrease with an
increase in plasma D-dimer [19, 20]. Binding of viral and bacterial components to Toll-like
receptors (TLRs) stimulate the procoagulant tissue factor to initiate the coagulation cascade.
This leads to thrombin activation which then cleaves the fibrinogen to fibrin [21]. Plasmin
cleaves the fibrin to produce fibrin degradation products. An increase in monocyte tissue factor
expression leads to increase in D-dimer in HIV infection [21]. Decrease protein S, protein C
and antithrombin activities as well as increase in plasma D-dimer are the predisposing factors
which will increase the risk HIV patients to thrombosis.
3.4. Prognostic markers of HIV infection
Prognostic markers are important tools for monitoring the HIV disease progression. Proper
monitoring of the disease may reduce the morbidity as well as mortality rate. Some markers
have been identified for monitoring the HIV disease progression. The markers is classified as
immunologic (CD4+ T cells), virologic (RNA viral load), serologic (serum β2microglobulin and
neopterin) [22] as well as biomarkers (lipid peroxidation) [23]. Among the markers, CD4+ T
cell count and RNA viral load are two most commonly used prognostic markers for clinical
progression of HIV infection [24, 25].
3.4.1. Immunologic marker of infection
The CD4+ T cell count is the most important laboratory indicator of immune function in HIV-
infected patients. It is also the strongest predictor of subsequent disease progression and
survival according to findings from clinical trials and cohort studies [22, 26].
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Measurement of CD4+ T cell count is necessary prior to the initiation of HAART. Since the
CD4+ T cell count reflects the status of overall immune function of HIV-infected patients, the
measurement is important as a guide for initiation of HAART to HIV patients as well as to
start or discontinue the prophylaxis for opportunistic infection (OI). Most of OIs occur in
patients with CD4+ T cell counts<200 cells/mm3 [27], however some patients may have OIs at
higher CD4+ T cell counts. For patients who are on therapy, adequate response is defined as
an increase in CD4+ T cell counts in the range of 50 to 150 cells/mm3 during the first year of
HAART. Patients who has faster response will show the response within the first 3 months of
treatment and subsequent increase in the range of 50 to 100 cells/mm3 per year until it reaches
a steady state [27]. Patients who has undergone the therapy at a low CD4+ T cell counts [28]
or at an older age [29] may have a minimal increase in CD4+ T cell counts despite virologic
suppression.
3.4.2. Virologic marker of infection
RNA viral load is the best indicator of progression to AIDS and death followed by CD4+ T cell
count, serum neopterin levels and serum β2microglobulin. It strongly predicts the rate of
decrease in CD4+T cell counts and progression to AIDS and eventual death, but the prognosis
of HIV is best predicted by combination of both plasma HIV-1 RNA and CD4+ T cells [21].
In addition, it is also a marker of response to HAART. The main goal of HAART is to achieve
and maintain durable viral suppression. A patient’s pre-HAART viral load level and the
magnitude of viral load decline after initiation of HAART provide prognostic information
about the probability of disease progression [30]. Thus, the most important use of the viral
load is to monitor the effectiveness of therapy after initiation of HAART. The minimal changes
in the viral load is considered to be statistically significant (2 standard deviations) when there
is a three-fold change (equivalent to a 0.5 log10 copies/mL change) in the viral load [31]. Optimal
viral suppression is defined as presence of persistent viral load below the level of detection
(HIV RNA <20 to 75 copies/mL, depending on the assay used) [31].
Data from previous studies and clinical trials reported that reduction in viral load following
initiation of HAART are associated with reduced risk of progression to AIDS or death [30].
Therefore, RNA viral load measurement is an established surrogate marker for treatment
response.
3.4.3. Serologic markers
Beta-2 microglobulin is a low molecular weight protein, which comprises the light chain of
class 1 MHC proteins and is noncovalently bound to the heavy chain [2]. It is present on the
surface of all nucleated cells. Dissociation during metabolism and degradation leads to its
release to all biological fluids. In HIV disease, an increased level of Beta-2 microglobulin in
cerebrospinal fluid (CSF) correlates with the disease progression and a decrease level indicates
successful therapy [32].
Similarly, neopterin, a marker of immune activation is a low molecular weight compound
derived from guanosine triphosphate [5]. It is produced by monocyte/macrophages upon
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stimulation with IFN-γ. The production is increased in HIV infection and infection by
intracellular organisms such as parasite, autoimmune disease, malignant tumours, allograft
rejection, neurological as well as cardiovascular disease [33]. However, it has slightly low
predictive value compared to beta-2 microglobulin [5]. Neopterin and beta-2 microglobulin
levels were proved to be significant predictors of AIDS risk in HIV-1 seropositive patients. The
predictive value of both parameters is equal to CD4+ T cell counts. Therefore, neopterin and
beta-2 microglobulin are recommended to be used as an additional marker to predict AIDS
risk for HIV-1 seropositive patients and is beneficial particularly in the setting where the CD4+
T cell count measurement is not available [34].
3.4.4. Biomarker
Oxidative stress is a condition in which there is increased amounts of reactive oxygen or
nitrogen species. This condition is now recognized to be a prominent feature of many acute
and chronic disease and even in normal ageing process. Lipid peroxidation was found to be
one of the biomarkers to assess oxidative stress status in human disease including HIV [23]. A
study done by Friis-Moller et al. [35] have shown that HIV-infected patients have oxidative
imbalance early in the disease; low serum and tissue antioxidants and elevation of peroxidation
products. Besides, high plasma levels of malondialdehyde (MDA), reduced plasma gluta‐
thione (GSH) and decreased superoxide dismutase activities were also found [36].
4. Haematologic aspects of HIV infection
4.1. Normal haemopoiesis
Haemopoiesis is the formation of blood or blood cells in the living body. It involves the
production of three (3) major cell lines which are red blood cells, white blood cells and platelets
[37]. In humans, this process occurs in the bone marrow. In certain diseases, the process can
be altered either directly or indirectly. Patients with HIV infection will have altered haemo‐
poiesis [38], affecting both red and white blood cells and platelet formation.
Haemopoietic stem cells (HSCs) are the earliest cells recognized in the bone marrow (Figure
2). HSCs produce all blood cells [37]. About 5% of the HSCs in the bone marrow are functioning
at one time, thus maintaining the haemopoietic system for the lifetime in a human body.
Growth factors, also play an important role for production and differentiation of blood cells
in the bone marrow. Erythropoietin, a type of hormone which is mainly produced by the
kidney and thrombopoietin, which is mainly produced by the liver, are the growth factors that
are necessary for production and proliferation of red blood cells and platelets respective‐
ly.White blood cells have five (5) major components which include neutrophil, monocyte,
eosinophil, basophil and lymphocyte. The lymphocytes are further subdivided into B-
lymphocytes and T-lymphocytes, which are important for functional activity.
In most circumstances, HIV infection causes reduction in blood cell formation [40]. These
include red blood cell (anaemia), platelet (thrombocytopenia) and white blood cell (leucope‐
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nia) or any combination of these lineages (Table 6). The cause of these changes in HIV infection
are not fully understood.
White blood cell Normal Value(x109/l) % Reduce lineage
1. Neutrophil 2.0 – 7.0 40 – 80 Neutropaenia
2. Monocyte 0.2 – 1.0 2 – 10 Monocytopaenia
3. Eosinophil 0.02 – 0.5 1 – 6
4. Basophil 0.02 – 0.1 <1 – 2
5. Lymphocyte 1.0 – 3.0 20 - 40 Lymphopaenia
Table 6. Haematological abnormalities in HIV infection and normal adult reference values.
4.2. Haematological changes in HIV infection
Haematological abnormalities are common complications of HIV infection. These abnormal‐
ities increase as the disease advances. On both antiretroviral-treated and untreated individuals,
different types of haematological abnormalities are common [41, 42, 43, 44] (Table 6).
The diagram illustrates the hematopoiesis process that occurs in the bone marrow which gives rise to production of
various cell lines from the marrow stem cell.
Figure 2. Production of red and white blood cells and platelets in the bone marrow [39]
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Since the impact of HIV infection can be found in the peripheral blood and bone marrow,
disorders of the haemopoietic system include anaemia, leucopenia, thrombocytopenia and
thrombosis. These could be because of direct effects of the virus on the bone marrow, sup‐
pression of bone marrow by secondary infections or neoplasms causing ineffective haemato‐
poiesis, nutritional deficiencies or side effects of the drugs used [44]. The disorders commonly
occur throughout the course of HIV infection.
4.2.1. Blood abnormalities
The majority of the HIV cases present haematological abnormalities in the middle or advanced
stages of the infection. However, some of the changes such as low haemoglobin and platelets
have been reported in the early stages of HIV infection [44].
4.2.1.1. Anaemia
Anaemia refers to decrease in the haemoglobin (Hb) concentration with reference to healthy
individuals of the same age group, sex, physiological state and environment (altitude).Normal
haemoglobin for men is more than 13 g/dL while for women is 12 g/dL [38]. This can be
classified based on the etiology or morphology of the red blood cell. The normal red blood cell
shows a normochromic normocytic morphology. Anaemia is one of the commonest abnor‐
malities seen in HIV, occurring in more than 50% of patients [40]. In a study done in HIV
patients without myelosuppressive therapies, 8% of asymptomatic HIV-seropositive patients,
20% of those with symptomatic middle-stage HIV disease, and 71% of those with Centers for
Disease Control (CDC)-defined AIDS were found to be anaemic [40]. Anaemia can be the
earliest haematological manifestation, especially in children with HIV infection. Normochro‐
mic normocytic anaemia is the usual feature, but sometimes the HIV patients can present with
a hypochromic microcytic anemia [45, 46, 47, 48, 49].
The causes of anemia in HIV patients are multifactorial. Inflammatory cytokines released by
lymphocytes such as tumour necrosis factor (TNF), Interleukin-1 (IL-1) and interferon gamma
play an important role in the pathogenesis of anaemia. These cytokines have been shown to
inhibit red cell production (erythropoiesis) in vitro [51]. TNF levels were found to be consis‐
tently elevated in HIV infection and this condition is correlated with viral load [52]. Presence
of dyserythropoiesis and opportunistic infections have also resulted in functional and
morphological abnormalities of red blood cells [41]. This can alter the normal function of red
blood cell as oxygen carrier or alter its normal biconcave shape. Other factors that contribute
to the development of anaemia include underlying chronic disease, mixed nutritional defi‐
ciencies, opportunistic infections and side effects from the treatment [53]. As HIV disease
progresses, the prevalence and severity of anaemia also increases [48, 54].
Disseminated Mycobacterium avium complex (MAC) disease may be present in HIV patients.
It has been reported that about 76% of patients with this infection have severe anemia [52].
Another isolated red cell disorder, chronic pure red cell aplasia has been reported in HIV
patients infected with parvovirus B19 [55]. This indicates that the underlying infection due to
immunosuppression can give rise to anaemia.
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Nutritional anaemia in HIV patients frequently arises from an inadequate balanced diet intake
and malabsorption. Infection and drug toxicity are common causes of gastrointestinal disease.
Vitamin B12 deficiency is seen in up to one-third of HIV-positive subjects. Iron and folate
deficiency are also common in this type of patients [38]. Bone marrow infiltration by tumour,
such as lymphoma, is more common among HIV patients as compared to the normal popu‐
lation.The infiltration can suppress the production of red blood cells which can lead to
anaemia. Anaemia is known to occur as an adverse effect of drug therapy for HIV infection or
its complications. Myelosuppression can be caused by dose limiting toxicity of zidovudine
[56]. Other drugs such as primaquine, dapsone and ganciclovir can lead to anaemia in HIV
patients [52]. HIV patients with lymphoma on chemotherapy may present with anaemia due
to the myelosuppressive treatment.
4.2.1.2. Thrombocytopaenia
Platelets are produced in the bone marrow. Normal platelet count is between 150 – 400 x 109/L.
Reduction in the number of platelet count can be due to ineffective and/or reduced production
of platelets in the bone marrow or increase destruction/ consumption of platelets in the
peripheral blood. In HIV disease, thrombocytopaenia is the second most frequent hematolog‐
ical complication of HIV infection. It is found in 3% to 40% of individuals with HIV infection
and could occur at any stage [57]. Presence of thrombocytopaenia is independent of the disease
progression.
The mechanism of thrombocytopenia in HIV infection is mainly due to ineffective platelet
production and at the same time increased platelet destruction [58]. There is a significant
platelet sequestration and destruction in the spleen in HIV-associated thrombocytopenia.
(a) (b) 
The peripheral blood smear in Figure 3(a) appears normal morphology, this condition is a normochromic, normocytic
anemia. The utilization of iron is impaired due to a cytokine-mediated blockage in transfer of iron from the storage
pool to the erythroid precursors in the bone marrow. The RBC's in Figure 3(b) appear smaller than the normal mor‐
phology and have an increased zone of central pallor. This feature shows a hypochromic (less hemoglobin in each
RBC) and microcytic (smaller size of each RBC) anemia.
Figure 3. (a) Normochromic normocytic red cells and (b) Hypochromic microcytic red cells [50]
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Platelet destruction normally occurs early in the course of the disease. The destruction is often
antibody mediated [59]. There are HIV-specific antibodies that have been shown to share a
common epitope with antibodies against glycoprotein on the platelet surface (platelet GPIIb/
IIIa) [59]. Nonspecific absorption of immune complexes onto platelets also occurs which
predisposes the cell to immune thrombocytopaenia. Interestingly, there was a study that
correlated the presence of lupus anticoagulant and anticardiolipin antibodies in HIV patients
with the presence of thrombocytopaenia [60]. The other common cause of reduced platelet
production in HIV patients is direct infection of megakaryocytes by the virus itself [61]. This
gives rise to abnormal megakaryocytes morphology in the marrow. Other causes of throm‐
bocytopenia include marrow infiltration by opportunistic infection or lymphoma, presence of
complications such as thrombothic thrombocytopaenic purpura, and myelosuppressive effects
of drug therapy.
4.2.1.3. Leucopaenia
Leucopaenia is the reduction in total white blood cell (WBC) count. In adults, normal WBC
count is between 4.5 to 11.0 x 109/L. Leucopaenia is frequently seen in HIV patients and
predominantly due to lymphopenia, decrease in the number of lymphocyte count, mainly
CD4+ lymphocytes. Leucopaenia generally correlates with the disease progression in HIV
patients [62]. Reduction in absolute number of CD4+ T-cells occurs as one of the earliest
immunologic abnormalities of HIV infection and is one of the important prognostic indicators
of risk of developing opportunistic infections.
Production of granulocytes and monocytes is also reduced, but less well recognized feature as
compared to lymphopaenia. Occurance of neutropaenia is hinged on several other factors
which are commonly seen in patients with advanced HIV disease. It can also occur due to
concurrent infections, immune mediated or therapy related factors. Another cause of neutro‐
paenia might be decreased bone marrow production of granulocytes due to inhibition of
granulocyte progenitors. It has been postulated that a glycoprotein present in the marrow of
infected patients might have an inhibitory effect [62]. Despite cellularity changes, morpholog‐
ical changes may occur in HIV patients. The changes are mainly due to dysplasia [38].
Peripheral blood smear will show some neutrophil changes such as detached nuclear frag‐
ments, abnormal nuclear fragmentation either hypofragmentation or hyperfragmentation, and
abnormal nuclear granulation.
4.2.1.4. Haematological changes in HIV infection with correlation to CD4 cell count
In 2012, Parinithia and Kulkarni had done a study among 250 HIV patients to determine the
haematological changes that occur in HIV patients as well as to evaluate its correlation with
the CD4 cell count. They reported that among the HIV patients studied, anaemia, lymphopenia
and thrombocytopenia was found in 210 (84%), 163 (65.2%) and 45 (18%) cases respectively
[61]. Majority of the cases (70%) had CD4 cell counts below 200 cells/mm3, 54 cases (21.6%) had
CD4 cell counts between 200 to 499 cells/mm3 and in 21 cases (8.4%), the CD4 count is more
than 500 cells/mm3. In patients with CD4 cell counts less than 200 cells/mm3, anaemia,
leucopenia, lymphopenia and thrombocytopenia was observed in 91.4% 26.8%, 80% and 21.7%
Trends in Basic and Therapeutic Options in HIV Infection - Towards a Functional Cure120
cases respectively [61]. This study revealed that there was a significant increase in the number
of cases of anaemia and lymphopenia with decreasing CD4 cell counts. Thrombocytopenia
was also seen but did not show significant increase with disease progression.
5. Bone marrow associated haematological abnormalities
Bone marrow abnormalities are frequently seen in HIV infected patients.However, these
changes do not seem to be specific, but maybe typical for HIV patients. The most common
findings are dysplasia affecting one or more cell lineages. Bone marrow examination is not
routinely done in HIV infected patients. It is usually performed to evaluate peripheral
cytopenias or when systemic infections or malignancies are suspected.
5.1. Cellular abnormalities
The cellularity of the bone marrow can be assessed based on trephine biopsy. It can be normal,
reduced or increased, depending on the patients’ condition. Normally the bone marrow will
show normal or increased cellularity. However, the marrow cellularity does not always
correlate with the peripheral blood findings. The commonly observed pancytopenia (reduction
in the 3 major cell lineages, which are red cells, white cells and platelets) in the peripheral blood
is often associated with an active marrow [45], suggesting dysmyelopoiesis or increased
peripheral destruction. Other than cellularity, the morphology and function of the cells can be
altered. These include presence of severe nutritional deficiencies in advanced stages of HIV
infection, bone marrow suppression by opportunistic infections or neoplasm, underlying
chronic and toxic side effects of antiretroviral compounds (or other medications used to treat
the complications of HIV disease). Megaloblastic changes where the red cell series are
macrocytic, are occasionally seen in the bone marrow aspiration of HIV patients and this may
reflect myelodysplastic changes or concurrent effect of treatment [45]. There is possibility of
HIV directly infecting the haematopoietic precursor cells and inhibiting their differentiation
and maturation [45].
The increased number of plasma cells has been observed in some HIV patients. This may be
related to repeated infections that always occur in immunocompromised patients. Haemo‐
phagocytosis is frequently seen in a bone marrow examination, especially in patients with
CMV and herpes simplex infection. Features of increased macrophage activity may also be
seen in tuberculosis [63] and histoplasmosis infection associated with HIV disease [64].
5.2. Opportunistic infections
An opportunistic infection is an infection caused by pathogens, particularly opportunistic
pathogens, such as bacterial, viral, fungal or protozoal infections that usually do not cause
disease in a healthy host with a healthy immune system. All HIV-infected individuals are in
the immunosuppressive state. They are susceptible to a wide array of opportunistic infections
and are at higher risk to pathogenic organisms that plague the general population [65].
Infectious agents reported to attack the bone marrow in patients with HIV include Mycobac‐
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terium avium complex, Mycobacterium tuberculosis, Mycobacterium xenopi and kansasi,
Histoplasma, Cryptococcus, Toxoplasma, Cytomegalovirus and Pneumocystis carinii [66].
These infections may cause marrow changes either directly by the the organism itself or
indirectly by causing reactive changes.
5.3. HAART and other medication that cause bone marrow changes
Introduction to highly active antiretroviral therapy (HAART) has resulted in a highly signifi‐
cant decline in mortality [67]. However, some of these drugs frequently cause haematologic
toxicity. Several studies have shown that zidovudine and dideoxycytidine inhibit erythroid
colony forming units (CFU-E) that are needed for erythroid formation and granulocyte
macrophage colony forming units that is important for granulocyte formation [68]. Leucopenia
can be seen in HIV patients treated with Ganciclovir. Pyrimethamine and sulfadiazine used
in the treatment of toxoplasmosis cause leucopenia and thrombocytopenia. Chemotherapeutic
agents used in the treatment of malignancies, especially lymphoma result in myelosuppression
which is often dose limiting. Alpha interferon used in the treatment of Kaposi sarcoma in HIV
patient is frequently associated with haematologic toxicity [69].
5.4. Lymphoma in HIV disease
Lymphoma is a group of diseases caused by malignant lymphocytes that accumulate in lymph
nodes [37]. Lymphadenopathy or enlargement of the lymph nodes is the main clinical feature.
It can be subdivided into Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
Patients with HIV disease have an increased incidence of lymphoma as compared to general
population, especially diffuse non-Hodgkin's lymphoma subtype [70]. This is often of high
grade lymphoma and mostly of B cell origin [70, 71]. The increased risk of lymphoma appears
to be related to many factors, which are mainly related to a variety of genetic lesions, including
infection by Epstein-Barr virus (EBV), c-myc gene rearrangement, bcl-6 gene rearrangement,
ras gene mutations, and p53 mutations/deletions [72]. The malignant lymphoma, probably
arises as a monoclonal outgrowth from a pool of proliferating B lymphocytes, which have been
stimulated by the infective agents such as EBV and CMV.These opportunistic infections
contribute to the pathogenesis of lymphoma more seen in HIV infection. Lymphoma in HIV
patients tends to metastasize to brain or spread extranodal [73]. The relapse rate is high and
overall patients will have a poor prognosis. However, with the introduction of HAART
treatment, the risk of lymphoma has decreased and the clinical outcome improved [73].
6. Conclusion
The HIV epidemic clearly has broad and significant implications and impact on individuals
infected and affected globally. Possibility of HIV patient developing severe HIV-related
disease or not, depends on the degree of suppression of the immune system as well as the
extensive reduction in the blood count. Therefore, it is important to identify those patients who
are at risk of having the disease for proper assessment of infection and/or disease progression
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and subsequent monitoring. Prompt and consistent treatment should be given to those who
are early diagnosed and side effects or drug toxicity assessment clearly made for effective
consideration of drug change or drug discontinuation. Recently, with the introduction of
HAART most of the immunological and haematological complications has been reduced,
though some patients still develop unpredictable complications.
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